



Patent Application
Attorney Docket No. PC23296A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 24th day of January 2005.

By

(Signature of person mailing)

Kelley D. Surprenant

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Anthony Marfat, et al. :

APPLICATION NO.: 10/648,408 : Examiner: To be assigned

FILING DATE: August 25, 2003 : Group Art Unit: 1614

TITLE: Beta-Lactamase Inhibitor Prodrug :

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure set forth in 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. § 1.97 and § 1.98, Applicant(s) hereby bring to the Examiner's attention the enclosed PTO-FB-A820 and the listed documents.

The Examiner is requested to consider the cited documents and to indicate such consideration by returning a signed and initialed copy of the PTO-FB-A820 Form with the next communication from the Patent Office. Further, it is requested that the cited documents be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12). Applicants note that US 2005/0004093 is a publication of co-pending U.S. Application No. 10/862,200 of same assignee.

A first office action on the merits has not been received; therefore, no fee for this Information Disclosure Statement is required. In the event that an office action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.



Patent Application
Attorney Docket No.PC23296A


Should there be any questions regarding the above or the present application, the Examiner is invited to contact the undersigned at the below-listed number.

Date: 2/2/2006

Respectfully submitted,

Frank W. Forman
Attorney for Applicant(s)
Reg. No. 42,547

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5669



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC23296A	SERIAL NO. 10/648,408
	APPLICANT Anthony Marfat, et al.	
	FILING DATE August 25, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	3	9	3	1	4	0	5	1/6/76	Ekstrom, et al.	424	271	
	US	4	5	2	1	5	3	3	6/4/85	Hamanaka, et al.	514	80	
	US	5	3	7	3	0	1	8	12/13/94	Cugola, et al.	514	419	
	US	5	3	7	4	6	4	8	12/20/94	Cugola, et al.	514	419	
	US	5	3	7	4	6	4	9	12/20/94	Cugola, et al.	514	719	
	US	5	4	0	1	8	6	8	3/28/95	Lund	558	280	
US	2005	0	0	0	4	0	9	3	1/6/05	Marfat, et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EP	0	3	7	9	1	3	2	7/25/90	European	C07D	501/04		
	GB	1	4	2	6	7	1	7	3/3/76	Great Britain	C07D	499/44		
JP	5	8	0	4	9	3	8	7	3/23/83	Japan	C07D	501/47		
	JP	3	2	0	6	0	3	8	3/9/91	Japan	C07D	499/00		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			English, A. R., et al., <i>Orally Effective Acid Prodrugs of the β-Lactamase Inhibitor Sulbactam</i> , <i>J. Med. Chem.</i> , vol. 33, pp. 344-347, (1990).
			Patent Abstracts of Japan, vol. 0154, no. 74 (C-0809), (1991), Abstract for JP3206038.
			English language abstract for EP0379132.
			English language abstract for JP58049387.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.